Document is current
Any future updates will be listed below
-
Authors
Kim, Ekaterina
ten Hacken, Elisa
Sivina, Mariela
Clarke, Astrid
Thompson, Philip A. http://orcid.org/0000-0003-2086-6031
Jain, Nitin
Ferrajoli, Alessandra
Estrov, Zeev
Keating, Michael J.
Wierda, William G.
Bhalla, Kapil N.
Burger, Jan A.
- License Information
-
More Information
Article History
Received: 22 May 2019
Revised: 18 November 2019
Accepted: 5 December 2019
First Online: 20 December 2019
Compliance with ethical standards
:
: AC is an employee of Gilead Sciences, Inc. and owns equity in the company; PAT has served as a consultant for AbbVie and Pharmacyclics, an AbbVie company; NJ has served as a consultant for AbbVie, Pharmacyclics, and Janssen Pharmaceuticals, Inc. and received research funding from Pharmacyclics; WGW has received honoraria, served as a consultant and received research funding from Gilead Sciences, Inc.; JAB has received research funding from Gilead Sciences and Pharmacyclics, travel expenses from Gilead Sciences and served as a consultant for Janssen Pharmaceuticals. The remaining authors declare no competing interests. The BET inhibitor GS-5829, idelalisib, and entospletinib were provided by Gilead Sciences, Inc.
